Acetylcysteine, commonly called NAC, works primarily by donating a sulfur-containing building block that your body uses to produce glutathione, its most important internal antioxidant. It also directly breaks apart the chemical bonds that make mucus thick and sticky. These two core actions explain why NAC shows up in such different medical settings: thinning mucus in lung diseases, rescuing the liver after acetaminophen overdose, and a growing list of experimental uses in psychiatry and neurology.
The Free Sulfhydryl Group
Everything NAC does traces back to a single chemical feature: a free sulfhydryl group, essentially a sulfur atom bonded to a hydrogen atom dangling off the molecule. This reactive sulfur group can swap bonds with other sulfur-containing structures in the body, which is the basis of both its mucus-thinning and antioxidant effects. Sulfur-containing compounds that lack this free group show little to no ability to break down mucus or boost antioxidant defenses, which confirms that this one structural detail is what makes NAC useful.
How NAC Breaks Down Mucus
Mucus gets its thick, gel-like consistency from proteins called mucins. These mucins are rich in the amino acid cysteine, and neighboring cysteine molecules link together through what are called disulfide bonds, essentially two sulfur atoms locked together like a clasp. These bonds cause mucus to clump into dense aggregates that are hard to cough up.
NAC’s free sulfhydryl group performs a direct swap called a thiol-disulfide exchange reaction. It breaks the sulfur-sulfur clasp holding mucin strands together, releasing free cysteine molecules and loosening the entire mucus network. The result is thinner, more liquid mucus that moves more easily through the airways. This is why NAC has been used as a mucolytic for decades in conditions like cystic fibrosis, chronic bronchitis, and other lung diseases where thick secretions are a problem.
Boosting Glutathione Production
Glutathione is the body’s primary internal antioxidant, present in virtually every cell. It neutralizes harmful reactive oxygen species, detoxifies foreign substances in the liver, and helps repair damaged proteins. Your body builds glutathione from three amino acids, and the one most often in short supply is cysteine.
NAC serves as a delivery vehicle for cysteine. Once absorbed, NAC is broken down into cysteine, which cells then use to manufacture fresh glutathione. This matters most when glutathione stores are depleted, whether from disease, toxic exposure, or aging. Oral NAC has been shown to raise glutathione levels in lung tissue specifically, which may help suppress the kind of oxidant-driven inflammation common in chronic respiratory diseases.
Saving the Liver After Acetaminophen Overdose
NAC’s best-known emergency use is as the antidote for acetaminophen (paracetamol) poisoning, and the mechanism ties directly to glutathione. At normal doses, your liver processes acetaminophen safely. But in an overdose, the liver’s usual detoxification pathways get overwhelmed, and a toxic byproduct called NAPQI accumulates. NAPQI is an aggressive molecule that binds to liver cells and destroys them. Normally, glutathione neutralizes NAPQI before it causes damage, but an overdose burns through glutathione reserves faster than the liver can replenish them.
NAC floods the liver with the raw material it needs to rebuild its glutathione pool. By restoring glutathione levels, NAC allows the liver to safely neutralize NAPQI before it causes irreversible damage. Timing matters enormously: treatment is most effective when started within 8 to 10 hours of the overdose. In hospital settings, intravenous NAC is typically given as a total dose of 300 mg/kg spread across 21 hours in a three-stage infusion.
Effects on Brain Chemistry
NAC also influences glutamate, the brain’s primary excitatory signaling chemical. In a region called the nucleus accumbens, which plays a central role in reward, motivation, and habit formation, NAC appears to help regulate glutamate levels by supporting the function of glial cells. These are the brain’s support cells, and among other jobs, they absorb excess glutamate from the spaces between neurons.
When glutamate signaling becomes overactive, it can drive compulsive and impulsive behaviors. NAC may help correct this by enhancing glial uptake of glutamate, essentially turning down the volume on an overexcited circuit. This mechanism has been studied in conditions like trichotillomania (compulsive hair-pulling), where a trial published in JAMA Psychiatry found that NAC reduced symptoms, supporting the idea that targeting glutamate pathways can address compulsive behaviors. Researchers are also exploring this mechanism in substance use disorders and obsessive-compulsive disorder, though results remain mixed and preliminary.
Absorption and Bioavailability
One of NAC’s notable limitations is how poorly it’s absorbed when taken by mouth. Oral bioavailability of the active, reduced form of NAC is only about 4%, with total NAC (including its oxidized forms) reaching roughly 9%. This means that the vast majority of an oral dose never makes it into the bloodstream intact. Once absorbed, NAC has a half-life of about 5.6 hours in healthy adults, meaning half of it is cleared from the blood in under six hours.
People with severe liver disease clear NAC much more slowly. Studies comparing cirrhotic patients to healthy controls found that the drug’s exposure (measured as area under the concentration curve) was nearly double in those with liver damage: 152 versus 94 mg/L/h. This makes sense, since a damaged liver processes substances less efficiently, but it also means dosing may need to be adjusted in these patients.
The low oral bioavailability is one reason intravenous NAC is preferred in emergencies like acetaminophen poisoning, where rapid, reliable delivery to the liver is critical.
Side Effects and Reactions
NAC is generally well tolerated, but the route of administration makes a big difference. Oral NAC causes nausea and vomiting in about half of acetaminophen-poisoned patients, with worse nausea at higher overdose severity. This is partly why oral dosing in poisoning cases can be challenging to complete.
Intravenous NAC carries a risk of anaphylactoid reactions, which look similar to allergic reactions but involve a different immune mechanism. Symptoms include rash, itching, wheezing, and occasionally low blood pressure. In one study of 187 patients, adverse events occurred in 3.7% of cases. Six of those seven reactions were skin-related and resolved quickly with antihistamines. True life-threatening reactions are rare.
Interaction With Nitroglycerin
NAC has a clinically significant interaction with nitroglycerin, a drug used to treat chest pain from angina. Nitroglycerin works by relaxing blood vessels, a process that depends on available sulfhydryl groups. Because NAC is a sulfhydryl donor, it amplifies nitroglycerin’s blood vessel-relaxing effects. The combination also produces a compound that strongly inhibits platelet clumping, which could be beneficial in preventing heart attacks.
In a clinical study of patients with unstable angina, those receiving both nitroglycerin and NAC had significantly fewer heart attacks than those on nitroglycerin alone (3 versus 10 patients). However, the combination also caused symptomatic drops in blood pressure in 7 of 24 patients, compared to none in the nitroglycerin-only group. A follow-up using continuous NAC infusion at a lower rate showed better tolerance, with no patients experiencing problematic blood pressure drops. This interaction means anyone using nitroglycerin should be aware that NAC can intensify its effects.
What NAC Does Not Do
Despite its theoretical antioxidant benefits, NAC has not consistently delivered the clinical improvements you might expect in chronic lung disease. A meta-analysis pooling nine studies with nearly 2,000 COPD patients found no significant difference between NAC and placebo in reducing acute exacerbations, improving lung capacity, or changing quality-of-life scores. Glutathione levels in the NAC-treated group did not differ meaningfully from those in the control group either. Some individual trials, particularly in Chinese patients receiving 1,200 mg daily, showed reductions in exacerbation risk, but the overall evidence does not support NAC as a reliable treatment for preventing COPD flare-ups.
This disconnect between a compelling mechanism and underwhelming clinical results may partly reflect NAC’s low oral bioavailability. If only 4 to 9% of an oral dose reaches the bloodstream, the amount actually reaching lung tissue may be too small to shift outcomes in a disease driven by years of accumulated damage.